Tacrolimus is one of the newer immunosuppressants that act by inhibiting T-cell activation and cytokine release. It is approved for the treatment of atopic dermatitis, and its safety and efficacy ...

Background: Tacrolimus and cyclosporine, both calcineurin inhibitors, can cause neurological side effects. While mild symptoms such as tremor are well recognised, severe complications including ...

Only two calcineurin inhibitors exist, cyclosporine and tacrolimus, and the available formulations are once-daily slow-release tacrolimus, twice-daily immediate-release tacrolimus and twice-daily ...

Credit: FDA. The BX rating indicates that the data are insufficient to show that the product provides the same therapeutic effect as Prograf. The Food and Drug Administration (FDA) has changed the ...

In a phase III trial, oral tacrolimus (Prograf) proved non-inferior to intravenous cyclophosphamide for treating lupus nephritis, researchers said. Among 158 patients randomized to tacrolimus ...

In light of the promising results of a pilot study, Talwalkar et al. investigated whether or not tacrolimus is indeed safe and efficacious in patients with primary sclerosing cholangitis (PSC).

More patients with atopic dermatitis achieved mild disease severity by 1 month of treatment with adjuvant dupilumab and tacrolimus vs dupilumab alone. A greater proportion of patients with atopic ...

Black kidney transplant recipients have a faster clearance rate of the immunosuppressive drug tacrolimus than white recipients, according to a new study led by Kathleen Tornatore, professor of ...